This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Phase II Study of Neoadjuvant Chemotherapy Regimen Choice in Breast Cancer

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified February 2014 by Hospital Affiliated to Military Medical Science, Beijing.
Recruitment status was:  Recruiting
Information provided by (Responsible Party):
Hospital Affiliated to Military Medical Science, Beijing Identifier:
First received: October 10, 2012
Last updated: February 17, 2014
Last verified: February 2014
The study purpose is to observe which neoadjuvant chemotherapy regimens is the better for invasive breast cancer. The neoadjuvant chemotherapy regimen is sustained anthracyclines plus taxanes or from anthracyclines plus taxanes to vinorelbine plus cisplatinum.

Condition Phase
Breast Cancer Phase 2

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective

Resource links provided by NLM:

Further study details as provided by Hospital Affiliated to Military Medical Science, Beijing:

Primary Outcome Measures:
  • pathological complete response rate [ Time Frame: one year ]

Secondary Outcome Measures:
  • clinical response rate, safety [ Time Frame: one year ]

Estimated Enrollment: 60
Study Start Date: May 2012
Estimated Study Completion Date: May 2014
Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Docetaxel 75 mg/m2, day 1 or paclitaxel 175mg/m2 day 1 plus Epirubicin 75 mg/m2, day 1 or doxorubicine 50mg/m2 day 1 for 6-8 cycles
docetaxel 75mg/m2,day 1 or paclitaxel 175mg/m2,day 1 plus doxorubicine 50mg/m2,day 1 or epirubicin 75mg/m2, day 1,for3-4 cycles then switch to vinorelbine 25mg/m2, day 1 and day 8 plus cisplatinum 75mg/m2, day 1 for 3-4 cycles

Detailed Description:
The investigators hope to get preliminary results for the breast cancer patients who are given different neoadjuvant chemothetapy regimens. The patients are randomized two chemotherapy regimens. One is anthracyclines plus taxanes for 6-8 cycles,the other is anthracyclines plus taxanes for 3-4 cycles ,then switch tovinorelbine plus cisplatinum for 3-4 cycles.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
diaganosis of invasive breast cancer, tumor size > 2.0cm by MRI or ultrasound or clinical examination.

Inclusion Criteria:

  • Diagnosis of invasive ductal or lobular breast cancer.
  • Previously untreated (no chemotherapy or hormonal therapy or radiation therapy) invasive breast cancer.
  • no anti-Her2 therapy if HER2 positive ( defined as 3+ IHC or FISH positive)
  • Performance Status ECOG <2
  • Age > 18 years
  • Tumor > 2.0 cm by MRI and/or sonographic or clinical exam measurements.or Karnofsky >50%
  • Lab test :

    • Absolute neutrophil count > 1,500/mm3

      • Total Bilirubin ≤ 2×ULN
      • AST and ALT ≤ 2.5×ULN
    • serum creatinine ≤ 1.5×ULN

Exclusion Criteria:

  • Pregnant or breast feeding patients are excluded
  • stage Ⅳ breast cancer
  • History of non-breast malignancies within the 5 years prior to study entry, except for the following: carcinoma in situ of the cervix, carcinoma in situ of the colon,melanoma in situ, and basal cell and squamous cell carcinomas of the skin
  • uncontrolled cardiac disease
  • Active infection or chronic infection requiring chronic suppressive antibiotics
  • History of hypersensitivity reaction to investigating drugs
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01732939

China, Beijing
Hospital affiliated academy military medical science Recruiting
Beijing, Beijing, China, 100071
Contact: Tao Wang, MD    8610-66947430      
Contact: Shaohua ZHANG, MD    8610-66947173      
Principal Investigator: Zefei Jiang, MD         
Sponsors and Collaborators
Hospital Affiliated to Military Medical Science, Beijing
Principal Investigator: Zefei Jiang, MD Hospital Affiliated Military Medical Science
  More Information

Responsible Party: Hospital Affiliated to Military Medical Science, Beijing Identifier: NCT01732939     History of Changes
Other Study ID Numbers: 307BCNeo-01
Study First Received: October 10, 2012
Last Updated: February 17, 2014

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases processed this record on August 22, 2017